Last Round
Grant
Nov 6, 2023
Total Funding Raised
$259.66M
Company Overview
Inotrem is a biotechnology company that develops innovative immunotherapies targeting the TREM-1 pathway to treat acute and chronic inflammatory syndromes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inotrem Comparables
Compare Inotrem with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adrenomed AG | 86% | |
| Matisse Pharmaceuticals | 85% | |
| 4TEEN4 Pharmaceuticals GmbH | 81% | |
Inotrem Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 6, 2023 | ||||
| Grant | Dec 1, 2022 | ||||
| Grant | Nov 2, 2021 | ||||
| Grant | Jul 12, 2021 | ||||
| Grant | Jul 1, 2020 | ||||
Debt | Feb 10, 2020 |
Key People
Founding team and executive leadership
Inotrem Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kreos Capital | Debt |
| BioMedPartners | Series A, Series B |
| Andera Partners | Series B, Series A |
| Kreos Capital | Debt |
| Inserm Transfert | Series A |
| Morningside Ventures | Series B |
| Bpifrance | Grant, Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2023
Received grant from the Crohn's & Colitis Foundation.
- Sep 12, 2019
$48.35M round led by Morningside.
Inotrem Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Inotrem's valuation, stock price, and market status.